For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell ...
NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (INKT) cell therapies, today announced the publication of a peer-reviewed article titled “CAR-iNKT Cells: Redefining the Frontiers ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid ...
Sickle cell disease is often thought of solely as a blood disorder, but new research from the Wood Neuro Research Group provides measurable evidence that it can reshape how brain networks function.
A naturally occurring byproduct of liver metabolism—the ketone body, β-hydroxybutyrate (BHB)—can strengthen the fitness and antitumor activity of CAR T cells. The findings, reported on March 6, 2026 ...
T Cells Gain Phagocytic Function via Specific Antigen RecognitionThe research team engineered CD8+ Jurkat T cells to express SVAR16 ...
HOUSTON, Sept. 12, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development ...